Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer

[1]  M. Delorenzi,et al.  Mutant Kras And Braf Gene Expression Profiles In Colorectal Cancer: Results Of The Translational Study On The Petacc 3-Eortc 40993-Sakk 60-00 Trial , 2010 .

[2]  P. Validire,et al.  Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Clarke,et al.  Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer , 2009, British Journal of Cancer.

[6]  B. Uzzan,et al.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.

[7]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Kerr,et al.  A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Labianca,et al.  Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Labianca,et al.  Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Sargent,et al.  Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Compton,et al.  Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Laurent-Puig,et al.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. , 2008, Cancer research.

[15]  W. Grady,et al.  Genomic and epigenetic instability in colorectal cancer pathogenesis. , 2008, Gastroenterology.

[16]  R. Labianca,et al.  Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials , 2008 .

[17]  P. Validire,et al.  Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin , 2008 .

[18]  M. Kloor,et al.  Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. , 2008, Gastroenterology.

[19]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[20]  Norman Wolmark,et al.  Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Daniel F Hayes,et al.  ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Sargent,et al.  Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. , 2006, Gastroenterology.

[24]  R. Gafà,et al.  Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Sargent,et al.  Current Issues in Adjuvant Treatment of Stage II Colon Cancer , 2006, Annals of Surgical Oncology.

[26]  E. Friedman,et al.  Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Kohonen-Corish,et al.  Low microsatellite instability is associated with poor prognosis in stage C colon cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Faivre,et al.  What Is the Best Way to Assess Microsatellite Instability Status in Colorectal Cancer?: Study on a Population Base of 462 Colorectal Cancers , 2004, The American journal of surgical pathology.

[30]  Richard D Kolodner,et al.  The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. , 2004, Gastroenterology.

[31]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Scott,et al.  A phase I trial of humanized monoclonal antibody huA33 in patients with early gastric cancer: Imaging studies, biodistribution, pharmacokinetics, immunohistochemistry, and quantitative tumor uptake. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[35]  E. Tiret,et al.  Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer , 2004, Gut.

[36]  M. Buyse,et al.  Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Goel,et al.  Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines , 2003, International journal of cancer.

[38]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[39]  P. Quirke,et al.  DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study , 2002, The Lancet.

[40]  J. Jass,et al.  Emerging pathways in colorectal-cancer development. , 2002, The Lancet. Oncology.

[41]  W. Bodmer,et al.  Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. , 2002, Cancer research.

[42]  B. Leggett,et al.  Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. , 2001, The American journal of pathology.

[43]  I. Tomlinson,et al.  Microsatellite instability and the clinicopathological features of sporadic colorectal cancer , 2001, Gut.

[44]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[45]  J. Coebergh,et al.  Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study , 2000, Gut.

[46]  L. Aaltonen,et al.  Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. , 2000, Gastroenterology.

[47]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[48]  J. Faivre,et al.  [Performance of the Hemoccult test in the screening of colorectal cancer and adenoma. Results of 5 screening campaigns in Saône-et-Loire]. , 1999, Gastroenterologie clinique et biologique.

[49]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[50]  S N Thibodeau,et al.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. , 1998, Cancer research.

[51]  D. Schaid,et al.  Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. , 1998, Cancer research.

[52]  L. Aaltonen,et al.  Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. , 1993, Cancer research.

[53]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.